MORGAN STANLEY PLC/CALL/AMGEN/440/0.1/20.06.25

MORGAN STANLEY PLC/CALL/AMGEN/440/0.1/20.06.25 Stock

DE000ME3CZC2

Market Closed - Börse Stuttgart 11:58:58 2024-06-07 EDT
0.54 ^EUR	-5.26%

Current month	+1.89%
1 month	+10.20%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart AMGEN INC.

Chart MORGAN STANLEY PLC/CALL/AMGEN/440/0.1/20.06.25

Latest news about AMGEN INC.

AbbVie's tight grip on Humira market raises concerns about biosimilars	06-07	RE
AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE	06-06	AQ
Transcript : Amgen Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 09:00 AM	06-06
AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE	06-05	PR

More news

Quotes 5-day view

Date	Price	Change
24-06-07	0.54	-5.26%
24-06-06	0.57	-5.00%
24-06-05	0.6	+3.45%
24-06-04	0.58	+3.57%
24-06-03	0.56	+5.66%

Delayed Quote Börse Stuttgart

Last update June 07, 2024 at 11:58 am

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	AMGEN INC.
Issuer	Morgan Stanley
WKN	ME3CZC
ISIN	DE000ME3CZC2
Date issued	2023-11-09
Strike	440 $
Maturity	2025-06-20 (376 Days)
Parity	10 : 1
Emission price	0.28 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	0.88 €
Lowest since issue	0.25 €
Delta	0.15x
Omega	7.537
Premium	46.18x
Gearing	51.81x
Moneyness	0.6932
Difference Strike	135 $
Difference Strike %	+30.68%
Spread	0.03 €
Spread %	5.36%
Theoretical value	0.5450
Implied Volatility	28.48 %
Total Loss Probability	90.80 %
Intrinsic value	0.000000
Present value	0.5450
Break even	445.89 €
Theta	-0.02x
Vega	0.07x
Rho	0.04x

Company Profile

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.

Sector

More about the company

Ratings for Amgen Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Consensus: Amgen Inc.

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

305 USD

Average target price

316.3 USD

Spread / Average Target

+3.69%

Consensus